NCT01251861 2026-03-18
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
124 trialsNCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT07455903 2026-03-06
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02531516 2026-02-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT05327647 2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT03348670 2025-08-17
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT01342367 2025-06-10
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
University of Chicago
Phase NA Active not recruiting
NCT00328614 2025-05-16
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT01420250 2025-05-15
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Thomas Jefferson University
Phase 1 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT00544830 2025-05-07
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02346253 2025-04-03
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Phase NA Active not recruiting
NCT06222593 2025-02-17
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
State University of New York at Buffalo
Phase 1/2 Recruiting
NCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT03141671 2024-05-14
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03358563 2024-05-03
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT06018116 2024-02-15
CANUCK-01
CHU de Quebec-Universite Laval
Phase 2 Withdrawn
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT00482807 2023-11-24
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Phase 1 Completed
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT00771017 2023-05-25
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT05019846 2023-04-18
SPA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Recruiting
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT03971110 2022-12-16
A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.
AstraZeneca
Phase 4 Terminated
NCT02064036 2022-10-18
CCRO025
University of California, Davis
Phase 1 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02582749 2022-07-11
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02614859 2022-03-29
BIMET-1
Fox Chase Cancer Center
Phase 2 Completed
NCT04248621 2021-07-29
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Wonju Severance Christian Hospital
Phase 4 Unknown
NCT00003653 2021-06-23
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03541928 2021-04-06
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
The Methodist Hospital Research Institute
Phase 2 Unknown
NCT03520478 2021-03-02
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown